Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US-2016237078-A9 · Aug 18, 2016 · US
Hepatitis B antiviral agents
US11236111B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11236111-B2 |
| Application number | US-202016891401-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2020 |
| Priority date | Jun 3, 2019 |
| Publication date | Feb 1, 2022 |
| Grant date | Feb 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
First claim
Opening claim text (preview).
What is claimed: 1. A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof: Compound Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2. A pharmaceutical composition, comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier or excipient. 3. A method of treating or preventing an HBV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds according to claim 1 . 4. The method of claim 3 , further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, literature-described capsid assembly modulator, reverse transcriptase inhibitor, TLR-agonist, inducer of cellular viral RNA sensor, therapeutic vaccine, and agents of distinct or unknown mechanism. 5. The method of claim 4 , wherein the compound and the at least one additional therapeutic agent
Assignees
Inventors
Classifications
- C07D498/20Primary
Spiro-condensed systems · CPC title
- C07D487/20Primary
Spiro-condensed systems · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11236111B2 cover?
- The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds f…
- Who is the assignee on this patent?
- Enanta Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D498/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).